Abstract

Quantumscape Corp. will report quarterly results on April 22, 2026 Post Market, with the street focused on a pre-revenue profile, a forecast EPS loss near -0.18, and any guidance on operating discipline and commercialization milestones that could influence sentiment and funding assumptions.

Market Forecast

Consensus embedded in current forecast data points to no revenue for the quarter (0.00 million US dollars, flat year over year), an EBIT loss of approximately 110.10 million US dollars with a 8.94% year-over-year improvement, and an EPS loss near -0.18 with a 12.06% year-over-year change; gross margin and net margin forecasts are not provided. The main business outlook remains centered on development execution and cost control, with revenue expected to stay at 0.00 million US dollars this quarter. The most promising commercial opportunity, which would ultimately be monetized through product sales or structured agreements, is not expected to contribute revenue this quarter, implying segment revenue of 0.00 million US dollars and year-over-year growth of 0%.

Last Quarter Review

In the previous quarter, Quantumscape Corp. reported revenue of 0.00 million US dollars (0% year over year), an unreported gross margin due to no revenue, a GAAP net loss attributable to shareholders of 100.00 million US dollars, an unreported net profit margin, and adjusted EPS of -0.17, reflecting a 22.73% year-over-year improvement. A notable financial highlight was the year-over-year improvement in EBIT to a loss of 110.45 million US dollars, a 14.17% improvement versus the prior-year quarter, underscoring cost discipline within a pre-revenue framework. Main business developments did not translate into top-line contributions, as revenue remained 0.00 million US dollars with 0% year-over-year change.

Current Quarter Outlook

Main business trajectory and operating discipline

The near-term profile for Quantumscape Corp. remains pre-revenue, which places heightened emphasis on operating efficiency and the path from development to commercial readiness. With a forecast EBIT loss of about 110.10 million US dollars and an estimated EPS of roughly -0.18 this quarter, investors are effectively gauging how operating expenses and program execution evolve in the absence of product revenue. Any incremental detail on cost run-rates, productivity improvements in development, or the timing of spend associated with scale-up activities can materially influence how the market frames the company’s cash needs and timeline to potential revenue. Management’s commentary on spend cadence will be a key read-through to future quarterly EBIT and EPS trajectories. Absent top-line contributions, the company’s quarterly performance is evaluated primarily through the lens of loss narrowing versus the prior year and adherence to internal milestones. The prior quarter showed year-over-year improvement in both EPS and EBIT, and the current forecast implies continued progress. Continuity in that trend—demonstrated by stable or improving per-share loss metrics—would reinforce that the company is keeping operating plans aligned with development progress. Conversely, a deviation toward higher-than-expected losses would likely increase investor focus on capital requirements and the durability of the current operating plan. Another important element of the main business trajectory is the clarity of program timelines and the associated expense phases. While revenue is again expected to be 0.00 million US dollars, a detailed update that sequences forthcoming activities can help the market assess when losses could begin to trend lower on an absolute basis. Investors will also listen closely for any indications of how the cost structure might evolve as development activities mature and how such changes could shape the loss profile across subsequent quarters.

Most promising commercial pathway and revenue implications

The most promising pathway to revenue remains the transition from development to commercialization, which is not expected to deliver sales this quarter. As a result, the revenue forecast is 0.00 million US dollars with a 0% year-over-year change. Within that context, what matters most in the outlook is whether management can credibly outline the gating steps that precede initial monetization—such as technical validation, performance consistency across build cycles, and steps that de-risk initial production readiness. Even without near-term sales, concrete progress checkpoints can affect how investors discount the future revenue opportunity. Because the current quarter carries no forecast revenue, gross margin and net margin metrics are not meaningful at this time; instead, the market will extrapolate from expense trends and operating commentary to project how margins could evolve once shipments begin. This places a premium on disclosures about yields, learning rates, and the scale-up approach that will ultimately determine unit economics. If the company can convey that key technical and process risks continue to be retired on schedule, it will support the case for eventual commercialization without undue slippage in the timetable implied by the market. The quarter is therefore less about the revenue print—projected to be 0.00 million US dollars again—and more about how management frames the next phases that would unlock monetization. Any indicator that reduces perceived execution risk—improvements in consistency, cycle performance, or manufacturability—can positively affect equity valuation multiples applied to future revenue. Conversely, a lack of specificity or any suggestion of extended timelines could prompt investors to reassess the probability and timing of future cash flows.

Stock price drivers this quarter: losses, timelines, and guidance tone

With no revenue expected, three factors are likely to dominate stock performance around the print and call: the size of the quarterly loss relative to expectations, the credibility and specificity of commercialization timelines, and the tone of guidance regarding spend, partnerships, or development checkpoints. On the loss profile, the consensus embedded in current estimates implies an EPS near -0.18 and EBIT around a -110.10 million US dollars loss; delivering in line or ahead on these measures would support the view that operating discipline remains intact. Any outperformance would help extend the narrative of year-over-year improvement established last quarter, when EPS and EBIT both improved versus the prior year. Timelines will be read with care. Market participants often translate incremental detail—target windows for technical validation steps, production-readiness milestones, or customer engagement phases—into probability-weighted revenue curves. Even modest refinements to those windows can produce meaningful changes in valuation for pre-revenue companies. A cohesive sequence that links forthcoming build targets to test feedback and process iterations will generally be viewed as constructive. Finally, guidance tone and qualitative color will matter. Investors will parse management’s language about progress, remaining hurdles, and spend allocation to infer how the balance of execution risk is shifting. Any indication that program risks are narrowing and that expense growth remains controlled relative to the plan can bolster confidence in the capital runway and the feasibility of the commercialization path. Conversely, signals that imply higher spending, slower-than-anticipated progress, or new technical challenges may overshadow otherwise stable headline metrics.

Analyst Opinions

Bullish views represent the majority of the opinions collected for the period, with a 100% share of tracked recommendations during the window reviewed. A notable example is Evercore ISI, where analyst Chris McNally reaffirmed a Buy rating and set a price target of 8.00 US dollars. This stance aligns with a narrative that the company is executing against its development plan sufficiently to justify continued support despite the absence of near-term revenue. The retention of a positive rating into this reporting event suggests that, for now, the balance of expectations tilts toward incremental progress over material negative surprises in spending or timelines. The bullish framing centers on three interlocking elements that are consistent with the numbers currently in the market. First, loss metrics appear to be trending in an improving direction year over year; last quarter’s EPS of -0.17 represented a 22.73% year-over-year improvement, and the current quarter’s embedded forecast implies an additional 12.06% year-over-year change. Second, EBIT trends are directionally similar, with the prior quarter’s -110.45 million US dollars loss reflecting a 14.17% year-over-year improvement and the current quarter’s forecast of -110.10 million US dollars indicating an 8.94% year-over-year change. Third, the company remains pre-revenue, which narrows the set of near-term surprises largely to expense management and timeline updates, areas that the bullish argument believes are under sufficient control to support constructive sentiment. In practical terms, bullish analysts are likely to look for confirmation that cost discipline and development cadence are holding to plans, which would validate the incremental improvements already visible in the recent prints. A steady hand on operating expenses can have an outsized impact on valuation for a pre-revenue enterprise by shaping the projected runway to commercialization. Any incremental specificity around next-phase milestones—particularly those that de-risk manufacturability or demonstrate reproducibility—would further strengthen the constructive stance, as investors could then assign higher probabilities to near- and medium-term monetization scenarios. A complementary aspect of the bullish view is how the market may react to the tone and detail of management’s commentary. If the company outlines clear, near-term checkpoints and conveys that the technical and process risk envelope is narrowing, the equity could benefit even amid a headline loss, because pre-revenue valuations often pivot on perceived execution momentum rather than single-quarter financials. Conversely, the bullish case acknowledges that setbacks or materially higher spending than implied in the current forecasts would challenge this view; however, the decision to reaffirm a positive rating into the event indicates that the base case anticipates alignment with guidance and controllable expense outlays. Overall, the majority perspective expects an in-line pre-revenue quarter with losses consistent with forecasts and a constructive update on program execution. Under that scenario, investors would likely refine—not overhaul—their valuation frameworks, maintaining a focus on the sustainability of year-over-year improvement in EPS and EBIT and the credibility of the timeline toward initial revenue. In this context, a Buy rating and an 8.00 US dollars target exemplify confidence that the company’s operational progress will continue to accumulate in ways that support future monetization and, ultimately, a transition out of a pre-revenue profile.